


PHARMACEUTICAL 2019

SCYNEXIS INC Rank 106 of 371







PHARMACEUTICAL 2019

SCYNEXIS INC Rank 106 of 371



The relative strengths and weaknesses of SCYNEXIS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SCYNEXIS INC compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 120% points. The greatest weakness of SCYNEXIS INC is the variable Research and Development, reducing the Economic Capital Ratio by 95% points.

The company's Economic Capital Ratio, given in the ranking table, is -43%, being 288% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	51,463
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,877
Liabilities, Non-Current	15,082
Other Assets	1,191
Other Compr. Net Income	0
Other Expenses	-6,736
Other Liabilities	986
Other Net Income	10,779
Property and Equipment	516
Research and Development	21,560
Revenues	257
Selling, General and Administrative Expense	8,680

Output Variable	Value in 1000 USD
Assets	53,170
Liabilities	21,945
Expenses	23,504
Stockholders Equity	31,225
Net Income	-12,468
Comprehensive Net Income	-12,468
Economic Capital Ratio	-43%